[1]王秀兰,薛尚才,焦新波,等.逍遥散加味联合曲安奈德球内注射治疗糖尿病黄斑囊样水肿20例临床观察[J].甘肃中医药大学学报,2018,35(06):65-69.[doi:10.16841/j.issn1003-8450.2018.06.14]
 WANG Xiulan,XUE Shangcai,JIAO Xinbo,et al.Clinical observation on 20 cases of diabetic cystoid macular edema treated by modified Xiaoyao San (逍遥散) combined with intraocular injection of triamcinolone acetonide[J].Journal of Gansu University of Chinese Medicine,2018,35(06):65-69.[doi:10.16841/j.issn1003-8450.2018.06.14]
点击复制

逍遥散加味联合曲安奈德球内注射治疗糖尿病黄斑囊样水肿20例临床观察
分享到:

《甘肃中医药大学学报》[ISSN:1003-8450/CN:62-1062/R]

卷:
35卷
期数:
2018年06期
页码:
65-69
栏目:
临床研究与报道
出版日期:
2018-12-25

文章信息/Info

Title:
Clinical observation on 20 cases of diabetic cystoid macular edema treated by modified Xiaoyao San (逍遥散) combined with intraocular injection of triamcinolone acetonide
作者:
王秀兰 薛尚才 焦新波 王雨晴 黄巧丽
甘肃省第二人民医院眼科, 甘肃 兰州 730000
Author(s):
WANG Xiulan XUE Shangcai JIAO Xinbo WANG Yuqing HUANG Qiaoli
Department of Ophthalmology, the Second People’s Hospital of Gansu, Lanzhou, Gansu, 730000, China
关键词:
糖尿病黄斑囊样水肿逍遥散加味曲安奈德球内注射黄斑视网膜厚度视力眼压临床疗效
Keywords:
diabetic cystoid macular edema (DME)modified Xiaoyao San (逍遥散)triamcinolone acetonideintraocular injectionthe macular lutea retinal thicknessvisual acuityintraocular pressure (IOP)clinical efficacy
分类号:
R276.745
DOI:
10.16841/j.issn1003-8450.2018.06.14
摘要:
目的 观察逍遥散加味联合曲安奈德球内注射治疗糖尿病黄斑囊样水肿(DME)的临床疗效。方法 选取DME患者40例、79只眼,采用随机数字表法分为2组。对照组20例、40只眼予曲安奈德球内注射治疗,治疗组20例、39只眼在对照组治疗方法的基础上联合逍遥散加味口服治疗。2组分别在治疗前及治疗后1,4,8周,行视力、黄斑视网膜厚度检查,并根据此2项指标判定2组的临床疗效。结果 治疗组治疗后1,4,8周视力明显升高,黄斑视网膜厚度明显减小,与治疗前比较差异均有统计学意义(P<0.05);治疗后4,8周,治疗组视力明显高于对照组,黄斑视网膜厚度明显小于对照组,2组比较差异均有统计学意义(P<0.05)。治疗后1,4,8周,对照组总有效率分别为70.0%,55.0%,35.0%,治疗组分别为66.7%,82.0%,76.9%,2组治疗后4,8周总有效率比较差异均有统计学意义(P<0.05)。结论 在曲安奈德球内注射的基础上联合逍遥散加味口服,可以明显改善患者的视力,减轻视网膜水肿,解决了单纯采用曲安奈德球内注射治疗远期疗效不佳的问题,取得了满意的临床疗效,且安全性良好。
Abstract:
Objective To observe the clinical efficacy of modified Xiaoyao San (逍遥散) combined with intraocular injection of triamcinolone acetonide in the treatment of diabetic cystoid macular edema (DME). Methods Forty cases and 79 eyes of DEM were chosen and divided into 2 groups according to random number table. The control group with 20 cases and 40 eyes was given intraocular injection of triamcinolone acetonide, while the treatment group with 20 cases and 39 eyes was given modified Xiaoyao San orally based on the treatment of the control group. Visual acuity and macular lutea retinal thickness were examined before treatment and at 1st, 4th and 8th week after treatment, respectively. The clinical efficacy of the two groups was determined according to these two indexes. Results The visual acuity of the treatment group was significantly increased at 1st, 4th, and 8th week after treatment, and the macular lutea retinal thickness was significantly decreased, there was statistical significance compared with that before treatment (P<0.05). The visual acuity of the treatment group at 4th and 8th week after treatment was significantly greater than that of the control group, the macular lutea retinal thickness was significantly less than that of the control group, there was statistical significance between the two groups (P<0.05). At 1st, 4th, and 8th week after treatment, the total effective rate of the control group was 70.0%, 55.0% and 35.0%, respectively, that of the treatment group was 66.7%, 82.0% and 76.9%, respectively. There was statistical significance in the total effective rate between the two groups at 4th, and 8th week after treatment (P<0.05). Conclusion Giving modified Xiaoyao San orally based on the treatment of intraocular injection of triamcinolone acetonide can significantly improve the visual acuity of the patients, attenuate retinal edema, and solve the problem of poor long-term efficacy of intraocular injection of triamcinolone acetonide alone, which has obtained satisfactory clinical efficacy with good security.

参考文献/References:

[1] 张承芬.眼底病学[M].2版.北京:人民卫生出版社, 2010:260.
[2] 李凤鸣.中华眼科学[M].2版.北京:人民卫生出版社, 2005:2101, 2165.
[3] 余秀梅, 陈志, 吴兰兰.氩绿激光联合中药治疗糖尿病黄斑水肿[J].国际眼科杂志, 2012, 12(9):1713-1715.
[4] Neelakshi Bhagat M D, Ruben A, Grigorjian M D, et al.Diabetic macular edema:pathogenesis and treatment[J].Surv Ophthalmology, 2009, 54:1-32.
[5] 张林平.中药五苓散加味治疗糖尿病黄斑水肿的临床分析[J].糖尿病新世界, 2014, 34(13):10.
[6] Banerjee P J, Woodcock M G, Bunce C, et al.A pilot study of intraocular use of intensive anti-inflammatory:triamcinolone acetonide to prevent proliferative vitreoretinopathy in eyes undergoing vitreoretinal surgery for open globe trauma.The adjuncts in ocular trauma (AOT)trial:study protocol for a randomised controlled trial[J].Trials, 2013, 14:42.
[7] 赵堪兴, 杨培增.眼科学[M].8版.北京:人民卫生出版社, 2015:219.
[8] 国家中医药管理局.中医病证诊断疗效标准[M].南京:南京大学出版社, 1994:87.
[9] 蔡蕾, 徐国兴.糖尿病黄斑水肿的危险因素和药物治疗现状[J].国际眼科杂志, 2015, 15(2):228.
[10] 张薇.玻璃体腔内注射曲安奈德在眼底病的应用[J].中国煤炭工业医学杂志, 2012(7):1115-1117.
[11] 王明芳, 谢学军.中医眼科学[M].北京:中国中医药出版社, 2004:741.
[12] 曾志成, 彭清华.中药汤剂口服联合玻璃体内注射曲安奈德治疗非增生性糖尿病视网膜病变弥漫性黄斑水肿30例临床观察[J].中医杂志, 2015, 56(11):937.

备注/Memo

备注/Memo:
收稿日期:2018-03-12。
基金项目:甘肃省中医药管理局项目(GZK-2016-47)。
作者简介:王秀兰(1965-),女,主任医师,医学学士,主要从事眼科临床及教学工作。
更新日期/Last Update: 1900-01-01